Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40673
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNasreddine, Rakan-
dc.contributor.authorFlorence, Eric-
dc.contributor.authorYombi, Jean Cyr-
dc.contributor.authorHenrard, Sophie-
dc.contributor.authorDarcis, Gilles-
dc.contributor.authorVan Praet, Jens-
dc.contributor.authorVandekerckhove, Linos-
dc.contributor.authorAllard, Sabine-
dc.contributor.authorDemeester, Rémy-
dc.contributor.authorMESSIAEN, Peter-
dc.contributor.authorAusselet, Nathalie-
dc.contributor.authorDelforge, Marc-
dc.contributor.authorDe Wit, Stéphane-
dc.date.accessioned2023-08-03T13:25:56Z-
dc.date.available2023-08-03T13:25:56Z-
dc.date.issued2022-
dc.date.submitted2023-08-03T13:24:16Z-
dc.identifier.citationHIV Glasgow, Glasgow, 23 – 26 October 2022-
dc.identifier.urihttp://hdl.handle.net/1942/40673-
dc.description.abstractConclusion • Several RCTs have demonstrated BIC/FTC/TAF to be a first-line option for treatment-naïve and experienced PLWH [1-4]. • Real-world studies provide complementary information to RCTs and ensure that those results can be generalized to broader populations seen in daily practice. • The aim of this study was to describe the Belgian HIV population treated with BIC/FTC/TAF and to evaluate its efficacy, durability, and tolerability in a real-world setting.-
dc.language.isoen-
dc.titleA retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium-
dc.typeConference Material-
local.bibliographicCitation.conferencedate2022, October 23-26-
local.bibliographicCitation.conferencenameHIV Glasgow-
local.bibliographicCitation.conferenceplaceGlasgow-
local.bibliographicCitation.jcatC2-
local.contributor.corpauthorBelgian Research on AIDS and HIV Consortium (BREACH)-
local.type.refereedNon-Refereed-
local.type.specifiedConference Poster-
local.provider.typePdf-
local.uhasselt.internationalno-
item.accessRightsOpen Access-
item.fullcitationNasreddine, Rakan; Florence, Eric; Yombi, Jean Cyr; Henrard, Sophie; Darcis, Gilles; Van Praet, Jens; Vandekerckhove, Linos; Allard, Sabine; Demeester, Rémy; MESSIAEN, Peter; Ausselet, Nathalie; Delforge, Marc & De Wit, Stéphane (2022) A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium. In: HIV Glasgow, Glasgow, 23 – 26 October 2022.-
item.fulltextWith Fulltext-
item.contributorNasreddine, Rakan-
item.contributorFlorence, Eric-
item.contributorYombi, Jean Cyr-
item.contributorHenrard, Sophie-
item.contributorDarcis, Gilles-
item.contributorVan Praet, Jens-
item.contributorVandekerckhove, Linos-
item.contributorAllard, Sabine-
item.contributorDemeester, Rémy-
item.contributorMESSIAEN, Peter-
item.contributorAusselet, Nathalie-
item.contributorDelforge, Marc-
item.contributorDe Wit, Stéphane-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
poster 9 PowerPoint Presentation.pdfConference material943.06 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.